Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996

ABSTRACT Antimicrobial resistance, including plasmid-mediated resistance, among the species of the Bacteroides fragilis group is well documented. An analysis of the in vitro susceptibility of B. fragilis group species referred between 1995 and 1996 as well as during a 7-year (1990 to 1996), prospective, multicenter survey of over 4,000 clinical isolates of B. fragilis group species was undertaken to review trends in the percent resistance to and geometric mean MICs of the antibiotics tested. There was a trend toward a decrease in the geometric mean MICs of most β-lactam antibiotics, while the percent resistance to most agents was less affected. Within the species B. fragilis, the geometric mean MICs showed significant (P < 0.05) decreases for piperacillin-tazobactam, ticarcillin-clavulanate, piperacillin, ticarcillin, ceftizoxime, cefotetan, and cefmetazole; a significant increase was observed for clindamycin and cefoxitin. For the non-B. fragilis species, a significant decrease in the geometric mean MICs was observed for meropenem, ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, ticarcillin, ceftizoxime, and cefmetazole; a significant increase was observed for cefoxitin. Significant increases in percent resistance were observed within theB. fragilis strains for ticarcillin and ceftizoxime and within the non-B. fragilis isolates for cefotetan. Significant increases in percent resistance among all B. fragilis group species were observed for clindamycin, while imipenem showed no significant change in resistance trends. The trend analysis for trovafloxacin was limited to 3 years, since the quinolone was tested only in 1994, 1995, and 1996. During the 7 years analyzed, there was no resistance to metronidazole or chloramphenicol observed. The data demonstrate that resistance among the B. fragilisgroup species has decreased in the past several years, the major exception being clindamycin. The majority of the resistance decrease has been for the β-lactams in B. fragilis, compared to other species. The reasons for these changes are not readily apparent.

[1]  D. Snydman,et al.  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Snydman,et al.  ANALYSIS OF THE IN VITRO ACTIVITY OF TROVAFLOXACIN (CP‐99,219) AGAINST BACTEROIDES SPECIES , 1996 .

[3]  D. Snydman,et al.  Attributable mortality of bacteremia associated with the Bacteroides fragilis group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Nichols,et al.  Wound and intraabdominal infections: microbiological considerations and approaches to treatment. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  I. Brook,et al.  Clinical relevance of susceptibility testing of anaerobic bacteria. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Snydman,et al.  Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis , 1992, Antimicrobial Agents and Chemotherapy.

[7]  Y. Gluzman,et al.  Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636 , 1990, Antimicrobial Agents and Chemotherapy.

[8]  H. Wexler,et al.  Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-beta-lactamase mediated cefoxitin resistance. , 1990, The Journal of antimicrobial chemotherapy.

[9]  D. Snydman,et al.  The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. , 1990, The Journal of antimicrobial chemotherapy.

[10]  N. Jacobus,et al.  Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group , 1990, Antimicrobial Agents and Chemotherapy.

[11]  F. Tally,et al.  Imipenem resistance in Bacteroides distasonis mediated by a novel beta-lactamase , 1990, Antimicrobial Agents and Chemotherapy.

[12]  N. Jacobus,et al.  In-vitro susceptibility of the Bacteroides fragilis group and the inoculum effect of newer beta-lactam antibiotics on this group of organisms. , 1989, The Journal of antimicrobial chemotherapy.

[13]  N. Jacobus,et al.  Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation , 1988, Antimicrobial Agents and Chemotherapy.

[14]  L. Piddock,et al.  Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility. , 1987, The Journal of antimicrobial chemotherapy.

[15]  M. Malamy,et al.  Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis , 1986, Antimicrobial Agents and Chemotherapy.

[16]  D. Smee,et al.  Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells , 1986, Antimicrobial Agents and Chemotherapy.

[17]  S. Gorbach,et al.  Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States , 1985, Antimicrobial Agents and Chemotherapy.

[18]  S. Gorbach,et al.  Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982 , 1984, Antimicrobial Agents and Chemotherapy.

[19]  S. Mitsuhashi,et al.  Properties of novel beta-lactamase produced by Bacteroides fragilis , 1983, Antimicrobial Agents and Chemotherapy.

[20]  S. Gorbach,et al.  Susceptibility of the Bacteroides fragilis group in the United States in 1981 , 1983, Antimicrobial Agents and Chemotherapy.

[21]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[22]  J. Bartlett,et al.  Susceptibility of Anaerobes to Cefoxitin and Other Cephalosporins , 1975, Antimicrobial Agents and Chemotherapy.

[23]  J. Bartlett,et al.  Anaerobic Infections: Old Myths and New Realities , 1974 .

[24]  J. Bartlett,et al.  Anaerobic infections. 1. , 1974, The New England journal of medicine.

[25]  M. Rathore,et al.  Renal and Splenic Abscess in A Previously Healthy Child , 1994 .

[26]  D. Citron,et al.  Wadsworth Anaerobic Bacteriology Manual , 1980 .

[27]  M. Malamy,et al.  Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. , 1979, The Journal of infectious diseases.